INNOVACIÓN
Karolinska Institute
Estocolmo, SueciaPublicaciones en colaboración con investigadores/as de Karolinska Institute (27)
2024
-
Alzheimer's disease genetic pathways impact cerebrospinal fluid biomarkers and imaging endophenotypes in non-demented individuals
Alzheimer's and Dementia
-
Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study
Alzheimer's and Dementia
-
Blood-based multivariate methylation risk score for cognitive impairment and dementia
Alzheimer's and Dementia
-
CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease
Alzheimer's and Dementia
-
GOIZ ZAINDU study: a FINGER-like multidomain lifestyle intervention feasibility randomized trial to prevent dementia in Southern Europe
Alzheimer's Research and Therapy, Vol. 16, Núm. 1
-
Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies
Fluids and Barriers of the CNS, Vol. 21, Núm. 1
2023
-
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology
Alzheimer's and Dementia, Vol. 19, Núm. 3, pp. 807-820
-
Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits
Alzheimer's and Dementia, Vol. 19, Núm. 6, pp. 2317-2331
2022
-
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease
Molecular neurodegeneration, Vol. 17, Núm. 1, pp. 27
-
Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (Molecular Neurodegeneration, (2022), 17, 1, (27), 10.1186/s13024-022-00521-3)
Molecular Neurodegeneration
-
Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 14, Núm. 1
-
Functional eigenvector centrality dynamics are related to amyloid deposition in preclinical Alzheimer’s Disease
Alzheimer's and Dementia
-
Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset
Frontiers in Aging Neuroscience, Vol. 14
-
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
JAMA Neurology, Vol. 79, Núm. 3, pp. 228-243
-
Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation
Molecular Psychiatry, Vol. 27, Núm. 4, pp. 1990-1999
2021
-
Csf proteomic alzheimer’s disease-predictive subtypes in cognitively intact amyloid negative individuals
Proteomes, Vol. 9, Núm. 3
-
TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels
Alzheimer's and Dementia, Vol. 17, Núm. 10, pp. 1628-1640
2020
-
APOE ϵ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease
Alzheimer's Research and Therapy, Vol. 12, Núm. 1
-
Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology
Journal of Alzheimer's Disease, Vol. 77, Núm. 3, pp. 1353-1368
-
Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics
Brain, Vol. 143, Núm. 12, pp. 3776-3792